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Inhibitory effect of taspine derivative TAD1822-7 on tumor 
cell growth and angiogenesis via suppression of EphrinB2 and 
related signaling pathways
The aim of this study was to investigate the inhibitory effect 
of TAD1822-7, a synthesized taspine derivative, on cancer 
through its effects on tumor cell growth and angiogenesis 
via suppression of EphrinB2. The obtained data showed that 
TAD1822-7 decreased Bel-7402 cell viability and colony forma-
tion ability and suppressed cell migration. TAD1822-7 effec-
tively inhibited blood vessel formation in an aortic ring assay 
to examine angiogenesis. Moreover, it also down regulated 
the expression of VEGFR2, VEGFR3, CD34, PLCγ, Akt, 
MMP2, MMP9, and CXCR4, and suppressed the expression 
of EphrinB2 and its PDZ protein, PICK1, in Bel-7402 cells. 
These results indicate that TAD1822-7 is a potential anti-
angiogenic agent that can inhibit the viability and migration 
of Bel-7402 cells via suppression of EphrinB2 and the related 
signaling pathways.
Keywords: TAD1822-7, EphrinB2, Bel-7402 cells, proliferation, 
migration, anti-angiogenesis
Hepatocellular carcinoma (HCC) is one of the common malignant cancers with high 
morbidity and mortality (1). Ephrins are the ligands for erythropoietin-producing hepa-
toma amplified sequence (Eph) family receptor tyrosine kinases (RTKs), which are mem-
brane-bound proteins (2). EphrinB2 is a subtype of EphrinB, which is a ligand for the 
EphB2, EphB3, and EphB4 kinases, and the only known ligand of EphB4 is EphrinB2 (3). 
Ephrin-mediated interactions between EphrinB2 and EphB4 are essential for tumor angio-
genesis (4). 
Angiogenesis plays a pivotal role in tumor progression, including primary capillary 
germination, branching and remodeling, or forming a mature vascular network (5). Stimu-
lation of EphrinB2, which phosphorylates its cognate receptor EphB4, provides signals for 
cell survival and migration in cancers (6). Meanwhile, the upregulation of EphrinB2 can 
activate VEGF/VEGFR signaling during tumor formation, which leads to activation of the 
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Taspine has been reported to have antitumor activity (8), and TAD1822-7 (Fig. 1a) is one 
of its derivatives, designed and synthesized as a lead compound containing a biphenyl scaf-
fold for better tumor suppression effects (8). However, no activity of TAD1822-7 against HCC 
has ever been reported and the related mechanism is still unknown. The current study is 
focused on the inhibitory effects of TAD1822-7 on HCC and the involved mechanisms.
EXPERIMENTAL
Materials
Taspine derivative TAD1822-7 was synthesized at the School of Pharmacy, Xi’an Jiaotong 
University (8). EphB4 Fluorescence-chimera (B4-Fc) was purchased from Beijing Biotech-
nology Co., Ltd. (MDL No. MFCD01867528, China). DAPI, MTT, RPMI-1640 medium and 
Dulbecco’s Modified Eagle’s medium (DMEM) were purchased from Sigma-Aldrich (USA). 
Thrombin was obtained from Guoao Pharmaceutical (China). Fetal bovine serum (FBS) was 
purchased from HyClone (USA). G418 was obtained from Gibco (USA). RIPA lysis buffer 
was purchased from Beijing BLKWB Biotechnology Co., Ltd (China). Enhanced Chemi-
luminescence (ECL) Plus Reagent kit was obtained from Pierce Biotechnology, Inc. (USA). 
EphrinB2 (Cat. #6957-1), MMP9 (Cat. #2551-1), and MMP2 (Cat. #1948-1) antibodies were 
purchased from Epitomics (USA). VEGFR2 (Cat. #26415-1-AP), VEGFR3 (Cat. #20712-1-AP), 
PICK1 (Cat. #10983-2-AP), Syntenin-1 (Cat. #22399-1-AP), CD34 (Cat. #14486-1-AP), CXCR4 
(Cat. #11073-2-AP), and GAPDH (Cat. #60042-1-IG) antibodies were purchased from Protein-
tech Group (USA). Akt (Cat. #4685), PLCγ1 (Cat. #5690), anti-mouse IgG (H+L; Cat. #14709) 
and anti-rabbit IgG (Cat. #14708) secondary antibodies were purchased from Cell Signaling 
Technology, Inc. (USA).
Cells and animals
Bel-7402, HepG2, A549, PANC-1, and SGC-7901 cell lines were purchased from Shanghai 
Institute of Cell Biology of the Chinese Academy of Science (China) and cultured in RPMI-1640 
medium supplemented with 10 % FBS. EphrinB2/HEK293 cells were constructed at Food and 
Drug Research & Test Center, Xi’an Jiaotong University, and cultured in DMEM supplemented 
with 300 mg mL–1 G418, penicillin/streptomycin and 10 % FBS.
Sprague-Dawley rats (40–60 g, 2–4 weeks of age, 3 male and 3 female) were purchased 
from the Animal Research Center of Xi’an Jiaotong University, and were sacrificed by CO2 
inhalation. The animal experimental protocol was approved by the Animal Ethics Com-
mittee of Xi’an Jiaotong University (license number: XJTULAC 2018-0542).
Cell viability test
The cell viability test was assessed by the MTT assay and cell colony survival assay. 
In the MTT assay, cells were treated for 48 h with 4, 8 and 16 μM TAD1822-7 dissolved in 
RPMI-1640 medium and the medium was used as a control, and then incubated with MTT 
solution; the formed crystals were dissolved with DMSO, and the absorbance at 490 nm 
was measured using the Molecular Devices FlexStation® 3 microplate reader (San Jose, CA, 
USA). In the colony survival assay, cells were plated at 200 cells per well in a 12-well plate 
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and treated with TAD1822-7 when the colonies were visible and countable. Colonies were 
fixed in methanol, stained with crystal violet, and observed under a microscope.
EphB4 fluorescence-chimera (B4-Fc) binding to EphrinB2
Binding ability of B4-Fc to EphrinB2 on the cytomembrane of Bel-7402 was assessed 
by EphrinB2 expression analysis. Bel-7402 cells were seeded in 96-well plates, incubated 
with 1 mg mL–1 B4-Fc dissolved in RPMI-1640 medium for 4 h at 37 °C and observed using 
a FITC fluorescence microscope. To determine the target role of TAD1822-7 on EphrinB2, 
HEK293/EphrinB2 cells were seeded in 96-well plates and co-cultured with 1 mg mL–1 B4-Fc 
and 4, 8 and 16 μM TAD1822-7 dissolved in DMEM for 6 h at 37 °C; the medium was used 
as a control. After that, the cells were washed twice with PBS, fixed in 4 % paraformaldehyde 
(PFA) for 15 min, stained with 1 μg mL–1 DAPI for 15 min, and observed using a fluorescence 
microscope.
Cell migration test
The cell migration test was performed using the Transwell system, in which there is 
an 8-mm pore of Millicell polycarbonate membrane for the cells to migrate through. Se-
rum-starved Bel-7402 cells were plated at a density of 1 × 104 cells per well in the upper 
chamber of the system and treated with TAD1822-7. After migration, the cells on the lower 
surface were fixed, stained with 0.2 % crystal violet and observed under a microscope.
Aortic ring culture
Dissected thoracic aortas from Sprague-Dawley rats were transferred immediately to 
PBS, the adventitia was removed, and the small vessels around the aorta were carefully 
transversely truncated with 1 mm cuts and cultured in polymerized fibrinogen with 
thrombin dissolved in DMEM in 48-well plates. More polymerized fibrinogen with thrombin 
was put on the aortic ring, and the aortic ring was cultured in the sandwich of the medium. 
After 7 days, the sprouting vessels were observed under a stereomicroscope and treated 
for 48 h with 4, 8 and 16 μM TAD1822-7 in DMEM and DMEM was used as a control. Neo-
-microvessels were observed and imaged throughout the experiment.
Western blotting analysis
After treatment with 0, 4, 8 and 16 μM TAD1822-7 for 48 h, the proteins in Bel-7402 cells 
were extracted using RIPA lysis buffer, denatured, separated by electrophoresis, and trans-
ferred to polyvinylidene fluoride membranes. After incubation with the corresponding 
primary antibodies and secondary antibodies, the membranes containing the proteins 
were exposed using an ECL kit. The Image-Pro Plus 5.1 (Rockville, MD, USA) was used for 
the quantification of protein expression.
Statistical analysis
Data were expressed as the mean ± SD and a two-tailed unpaired Student’s t-test was 
used to determine significance in statistical comparisons, with statistical significance 
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 accepted at p < 0.05 (*p < 0.05, **p < 0.01, and ***p < 0.001). All statistical analyses were com-
puted using GraphPad Prism 6.0 (USA).
RESULTS AND DISCUSSION
TAD1822-7 inhibited cell viability and colony formation
Cell viability of Bel-7402, HepG2, A549, PANC-1, and SGC-7901 cells treated with 
TAD1822-7 were investigated using the MTT assay (Fig. 1b), which revealed an inhibitory 
effect, especially in Bel-7402 cells. Meanwhile, when treated with 0, 4, 8 and 16 μM TAD1822-
7 until the colonies were visible and countable, colony formation was also similarly inhi-
bited (Fig. 1c). Hence, TAD1822-7 has a potential antitumor activity in HCC and it may be 
regulated by EphrinB2.
TAD1822-7 and B4-Fc bind competitively to EphrinB2 
B4-Fc staining of Bel-7402 cells revealed high expression of EphrinB2 (Fig. 2a). Protein 
expression of EphrinB2 was effectively downregulated in both Bel-7402 cells (Fig. 2b,c) and 
EphrinB2/HEK293 cells (Fig. 2d,e) after the treatment of 0, 4, 8 and 16 μM TAD1822-7, which 
indicated that TAD1822-7 could suppress EphrinB2 expression. In addition, EphrinB2/
HEK293 cells were treated with 0.5 mg mL–1 B4-Fc and 0, 4, 8 and 16 μM TAD1822-7 simul-
taneously for 4 h, and then stained with DAPI. The results showed that TAD1822-7 inhi-
bited the binding of B4-Fc to EphrinB2 in EphrinB2/HEK293 cells (Fig. 2f), indicating that 
TAD1822-7 and B4-Fc could bind competitively to EphrinB2 and TAD1822-7 to inhibit 
EphrinB2 activation.
Fig. 1. TAD1822-7 suppressed the proliferation and colony formation of Bel-7402 cells and EphrinB2/
HEK293 cells. a) chemical structure of TAD1822-7, b) inhibition of TAD1822-7 on Bel-7402, HepG2, 
A549, PANC-1, and SGC-7901 cells, c) representative images showed colony formation of Bel-7402 cells 
and EphrinB2/HEK293 cells by TAD1822-7.
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TAD1822-7 inhibited Bel-7402 cell migration
TAD1822-7 dose-dependently inhibited the migration ability of Bel-7402 cells in the 
transwell migration assay (Fig. 3a,b). MMP2 and MMP9 are critical components in cancer 
cell invasion and migration (9), and CXCR4 is associated with cancer cell migration (10). In 
Fig. 2. TAD1822-7 inhibited the expression of EphrinB2: a) representative images of Bel-7402 cells with 
B4-Fc, b) Western blot analysis of EphrinB2 expression level in Bel-7402, c) quantification of IOD value 
for b), d) Western blot analysis of EphrinB2 expression level in EphrinB2/HEK293 cells, e) quantifica-
tion of IOD value for d), f) representative images of EphrinB2/HEK293 cells treated with B4-Fc and 
TAD1822-7. Significant difference vs. control group: p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001).
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this study, TAD1822-7 inhibited the expression of MMP2, MMP9, and CXCR4 in Bel-7402 
cells in a dose-dependent manner (Fig. 3c,d), which was thought to confer the anti-migra-
tion effect.
TAD1822-7 inhibited angiogenesis in the aortic ring model
In the aortic ring assay, the entire angiogenesis process can be reproduced in vitro 
through the culture of rat aortic explants in a three-dimensional cell growth matrix under 
chemically defined growth factor conditions. After the sprouting vessels were observed, 
0, 4, 8 and 16 μM TAD1822-7 were added and cultured for 48 h. The result showed that 
TAD1822-7 inhibited the number of sprouting vessels (Fig. 4a), which indicated an inhibi-
tory effect on angiogenesis. Pitulescu, M.E. et al. reported that EphrinB2 was crucial in 
tumor angiogenesis, which can be regarded as a promising prognostic indicator and a 
target to modulate angiogenesis in cancer therapies (11).
CD34 protein expression is found on early hematopoietic and vascular-associated 
tissue and it also facilitates cell migration (12). VEGFR2 is the main mediator for the mito-
Fig. 3. TAD1822-7 suppressed Bel-7402 cell migration and the expression of MMP2, MMP9, and 
CXCR4: a) representative images of cells that migrated through the polycarbonate membranes in 
Transwell assays stained with 0.2 % crystal violet (magnification, x200), b) quantification of the IOD 
value for cells that migrated through the polycarbonate membranes in a), c) Western blot analysis of 
the expression levels of MMP2, MMP9, and CXCR4 in Bel-7402 cells, d) quantification of IOD values 
for c), significant difference vs. control group: p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001).
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genic, angiogenic and enhanced permeability properties of VEGF-A, and VEGFR3 is also 
reported to be involved in angiogenesis in cancer; the blocking of these proteins is thought to 
suppress angiogenic sprouting and vascular network formation (8). TAD1822-7 suppressed 
Fig. 4. The effect of TAD1822-7 on angiogenesis and the involved signal pathway proteins: a) represen ta-
 tive images show angiogenesis of the rat aortic ring under the treatment of TAD1822-7, b) Western blot 
analysis of the expression levels of VEGFR2, VEGFR3, and CD34 in Bel-7402 cells, c) quantification of 
IOD value for b), d) effect of TAD1822-7 on PDZ-binding motif protein of EphrinB2, PICK1, and Syntenin, 
e) quantitation data of densitometry analysis of the bands from d), f) effect of TAD1822-7 on PLCg and 
Akt, g) quantitation data of IOD value for f), significant difference vs. control group: p < 0.05 (*p < 0.05, 
**p < 0.01, ***p < 0.001).
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the expression of VEGFR2 and VEGFR3 in Bel-7402 cells in a dose-dependent manner after 
treatment for 48 h, and CD34 expression was also downregulated by TAD1822-7 (Fig. 4b,c).
TAD1822-7 regulated EphrinB2 PDZ-binding motif protein of Bel-7402 cells
EphrinB2 plays a crucial role in tumor angiogenesis, for which the presence of the 
C-terminal PDZ motif is required to allow recruitment of the related functional proteins 
around the EphrinB2 intracellular region. Syntenin-1 and PICK1 are the PDZ-binding motif 
proteins of EphrinB2, and may affect the activation of EphrinB2 (13). Expression of PICK1 
was suppressed drastically by TAD1822-7, but there was a minimal effect of TAD1822-7 on 
Syntenin-1 (Fig. 4d,e), which indicated that TAD1822-7 inhibited the activation of EphrinB2 
through its PICK1 intracellular tyrosine kinase domain.
TAD1822-7 inhibited the related downstream signal pathways
VEGFR2 is essential for many angiogenic processes in tumor vascularization that 
regulate the downstream signaling pathway to affect the cell function. TAD1822-7 has the 
ability to inhibit the protein expression of PLC-γ and Akt (Fig. 4f,g). PLCγ/PKC and PI3K/
Akt signaling pathways are two of the diverse molecular signaling pathways related to 
tumor cell growth, and the activation of these two pathways may lead to aberrant cell 
proliferation (14). TAD1822-7 inhibited the expression of PLC-γ and Akt in Bel-7402 cells. 
Activation of VEGFR3 is known to cause PI3K-dependent activation of Akt and PKC (15). 
We suspected that TAD1822-7 inhibited the expression of EphrinB2, thereby suppressing 
the related PI3K/Akt and PLCγ/PKC signaling pathways. Inhibition of EphrinB2 by 
TAD1822-7 will negatively regulate VEGFR2, VEGFR3, and CD34 to inhibit angiogenesis.
CONCLUSIONS
EphrinB2 is an angiogenesis-related transmembrane protein, which is upregulated 
and requires the presence of its C-terminal PDZ motif for activity in tumor cells. TAD1822-
7 is a synthesized taspine derivative for tumor growth inhibition, which inhibits cell via-
bility and migration in Bel-7402 cells via competitive binding to EphrinB2 and regulating 
EphrinB2 related signaling molecules expression. Meanwhile, TAD1822-7 was demonstrated 
to have the potential function of anti-angiogenesis. Furthermore, the results suggest that 
TAD1822-7 is a potential anti-tumor agent for hepatocellular carcinoma.
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